NASDAQ · ASTH

Astrana Health Inc.

$38.19 -$2.12 (-5.26%) 1D Pre-market
Charting by TradingView

Key Metrics

$2.00B
Market cap
90.49×
P/E · TTM
$3.74B
Revenue · TTM
$22.09M
Net income
EPS · TTM $0.45
Dividend yield 0.4%
Free cash flow $162.94M
Beta · 1Y 0.85
EBITDA · TTM $91.44M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 2
    The stock moved +29.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 2
  • Feb 9
    The stock moved -11.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.00B
Enterprise value$2.55B
Shares outstanding49.6M
52-wk range$18.08 – $51.60
Avg volume · 20D364.6K
Net cash −$549.25M
Book value / share$16.38
IndustryServices-Management Consulting Services
ExchangeNASDAQ
About Astrana Health Inc.
IPO dateNov 26, 2007
Employees3000

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E90.49
P/S0.53
P/FCF12.27
EV/EBITDA27.86
EV/Sales0.68
Graham №$12.91

Profitability

Gross —
Operating 0.9%
Net 0.6%
FCF 4.4%
ROE / ROIC 2.9% · 1.5%

Financial Health

Current ratio1.35
Quick ratio—
Debt / equity1.28
Debt / EBITDA 11.24
Net cash −$549.25M
Working capital$258.73M

Cash Flow · TTM

Operating CF $176.68M
Capex −$13.74M
Free cash flow $162.94M
Buybacks —
Dividends paid $7.89M
Shareholder yield 0.4%

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

2.6
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$12.91 vs $38.19
Trades 3.0× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings